Compass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc.
Details : Compass Therapeutics obtains global rights to TR009, a novel bispecific antibody and inhibitor of the notch pathway targeting DLL4 and VEGF-A.
Product Name : TR009
Product Type : Antibody
Upfront Cash : Undisclosed
May 13, 2021
Details : Elpiscience obtains the exclusive development and commercialization rights of TR009 for Greater China across all oncology indications and will lead the clinical development and commercialization to accelerate the path to approval of TR009 in its territor...
Product Name : ABL001
Product Type : Antibody
Upfront Cash : $7.0 million
January 20, 2021